Provided by Tiger Fintech (Singapore) Pte. Ltd.

Exelixis

36.19
+0.04000.11%
Post-market: 36.190.00000.00%19:12 EDT
Volume:2.26M
Turnover:81.71M
Market Cap:10.13B
PE:20.56
High:36.48
Open:36.03
Low:35.73
Close:36.15
Loading ...

EXEL or TECH: Which Is the Better Value Stock Right Now?

Zacks
·
07 Feb

4 PEG-Based GARP Stocks to Stay Ahead in Uncertain Markets

Zacks
·
06 Feb

Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks
·
06 Feb

Curious about Exelixis (EXEL) Q4 Performance? Explore Wall Street Estimates for Key Metrics

Zacks
·
06 Feb

BMY Gets Positive CHMP Opinion for Opdivo, Yervoy Combo and Breyanzi

Zacks
·
04 Feb

Exploring High Growth Tech Stocks in February 2025

Simply Wall St.
·
04 Feb

Here's Why Exelixis (EXEL) is a Strong Value Stock

Zacks
·
29 Jan

Repligen (RGEN) Surges 3.7%: Is This an Indication of Further Gains?

Zacks
·
29 Jan

Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?

Zacks
·
28 Jan

Exelixis Stock Falls as Oppenheimer Downgrades Rating to Perform

Zacks
·
28 Jan

Exelixis Is Maintained at Buy by Truist Securities

Dow Jones
·
28 Jan

Exelixis' Revenue Growth Likely to Be Meaningfully Ahead of Consensus, Morgan Stanley Says

MT Newswires Live
·
28 Jan

Exelixis Price Target Maintained With a $40.00/Share by HC Wainwright & Co.

Dow Jones
·
27 Jan

Stifel Nicolaus Sticks to Their Hold Rating for Exelixis (EXEL)

TIPRANKS
·
27 Jan

Exelixis: Hold Rating Maintained Amidst Comparable Efficacy and Risks of Zanza and Cabo

TIPRANKS
·
27 Jan

Exelixis Inc. : Morgan Stanley Raises to Overweight From Equal-Weight

THOMSON REUTERS
·
27 Jan

Morgan Stanley Upgrades Exelixis to Overweight From Equalweight, Raises Price Target to $40 From $30

MT Newswires Live
·
27 Jan

Exelixis’s Strategic Advancements in mCRC Market Capture Analyst’s Buy Rating

TIPRANKS
·
27 Jan

Exelixis upgraded to Overweight from Equal Weight at Morgan Stanley

TIPRANKS
·
27 Jan

Optimistic Outlook for Exelixis Driven by Growth Potential in Cabometyx and Zanzalintinib

TIPRANKS
·
27 Jan